

Special Issue

Amino Acids Metabolism and Cancer Therapy

Message from the Guest Editor

Amino acids are essential components in various biochemical pathways. The deprivation of certain amino acids is an effective strategy for the treatment of amino-acid-dependent cancers which exploits the compromised metabolism of malignant cells. Several studies have focused on amino acids' metabolism in cancer cells, drug design, preclinical and clinical evaluation of amino-acid-degrading enzymes, namely L-asparaginase, L-methionine γ -lyase, L-arginine deiminase, and L-lysine ϵ -oxidase. Potential contributors are invited to submit papers concerning modulators of amino acid metabolism in any pharmaceutical or related context. Particularly welcome are preclinical and clinical reports involving amino-acid-degrading enzymes, inhibitors/enhancers of amino acid metabolism, as well as dietary restrictions or supplementation of amino acids for cancer therapy. Novel approaches for metabolic control in cancer patients are also appreciated.

Guest Editor

Dr. Vadim S. Pokrovsky

N.N. Blokhin Cancer Research Center, Moscow, Russia
People's Friendship University, Moscow, Russia

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/48893

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)